查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1347373

HIV 藥物市場：2023-2028 年全球行業趨勢、佔有率、規模、成長、機遇和預測

HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

市場概況：

2022年全球愛滋病藥物市場規模達到305億美元。展望未來，IMARC Group預計到2028年市場規模將達到388億美元，2023-2028年復合年成長率（CAGR）為3.95%。

人類免疫缺乏病毒（HIV）是一種慢性且危及生命的疾病，可以通過血液和性接觸從一個人傳播到另一個人。它是一種攻擊稱為 CD-4 細胞的免疫細胞的病毒，使身體容易受到感染和其他疾病。多年來，全球愛滋病毒患病率不斷上升，對愛滋病毒藥物的需求產生了積極影響。愛滋病毒藥物有助於防止愛滋病毒的繁殖，從而降低其傳播風險。

促進全球愛滋病毒藥物市場成長的主要因素之一是愛滋病毒患病率及其診斷的增加。除此之外，市場還受到政府為提高人們對病因、症狀和治療認知而採取的舉措數量增加的影響。此外，學名藥的引入具有成本效益且化學成分與品牌藥相同，這是增加愛滋病毒藥物需求的另一個因素。

本報告回答的關鍵問題

  • 2022年全球愛滋病毒藥物市場規模有多大？
  • 2023-2028年全球愛滋病藥物市場的預期成長率是多少？
  • COVID-19 對全球 HIV 藥物市場有何影響？
  • 推動全球愛滋病藥物市場的關鍵因素是什麼？
  • 根據藥物類別，全球愛滋病毒藥物市場的詳細情形如何？
  • 全球愛滋病毒藥物市場的配銷通路分類如何？
  • 全球愛滋病藥物市場的關鍵區域有哪些？
  • 全球愛滋病藥物市場的主要參與者/公司有哪些？

目錄

第一章：前言

第 2 章：範圍和方法

  • 研究目的
  • 利益相關者
  • 數據源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球 HIV 藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 價格分析
  • 按藥物類別分類的市場細分
  • 按配銷通路分類的市場細分
  • 按地區分類的市場細分
  • 市場預測
  • SWOT分析
    • 概述
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • 價值鏈分析
    • 概述
    • 研究與開發
    • 原料採購
    • 製造業
    • 行銷
    • 分配
    • 最終用途
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅

第 6 章：按藥物類別分類的市場細分

  • 核苷逆轉錄酶抑製劑
    • 市場走向
    • 市場預測
  • 多類別組合產品
    • 市場走向
    • 市場預測
  • 蛋白酶抑製劑
    • 市場走向
    • 市場預測
  • HIV 整合酶鏈轉移抑製劑
    • 市場走向
    • 市場預測
  • 非核苷逆轉錄酶抑製劑
    • 市場走向
    • 市場預測
  • 進入抑製劑 - CCR5 共受體拮抗劑
    • 市場走向
    • 市場預測
  • 融合抑製劑及其他
    • 市場走向
    • 市場預測

第 7 章：按配銷通路分類的市場細分

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥店
    • 市場走向
    • 市場預測
  • 網上藥店
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：按地區分類的市場細分

  • 北美
    • 市場走向
    • 市場預測
  • 歐洲
    • 市場走向
    • 市場預測
  • 亞太地區
    • 市場走向
    • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場預測
  • 拉丁美洲
    • 市場走向
    • 市場預測

第 9 章：HIV 藥物生產流程

  • 產品概述
  • 原料要求
  • 製造流程
  • 關鍵成功因素和風險因素

第 10 章：競爭格局

  • 市場結構
  • 關鍵參與者的市場細分
  • 關鍵參與者簡介
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • ViiV Healthcare
    • AbbVie
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Cipla Limited
    • Daiichi Sankyo
    • Emcure
    • Hetero Drugs
    • Mylan
Product Code: SR112023A953

Market Overview:

The global HIV drugs market size reached US$ 30.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 38.8 Billion by 2028, exhibiting a growth rate (CAGR) of 3.95% during 2023-2028.

Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV, thereby reducing the risk of its transmission.

One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.

Competitive Landscape:

The competitive landscape of the market has also been examined with some of the key players being Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Gilead Sciences, Inc., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan.

This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.

Key Questions Answered in This Report

  • 1. What was the size of the global HIV drugs market in 2022?
  • 2. What is the expected growth rate of the global HIV drugs market during 2023-2028?
  • 3. What has been the impact of COVID-19 on the global HIV drugs market?
  • 4. What are the key factors driving the global HIV drugs market?
  • 5. What is the breakup of the global HIV drugs market based on the drug class?
  • 6. What is the breakup of the global HIV drugs market based on the distribution channel?
  • 7. What are the key regions in the global HIV drugs market?
  • 8. Who are the key players/companies in the global HIV drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global HIV Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Price Analysis
  • 5.5 Market Breakup by Drug Class
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast
  • 5.9 SWOT Analysis
    • 5.9.1 Overview
    • 5.9.2 Strengths
    • 5.9.3 Weaknesses
    • 5.9.4 Opportunities
    • 5.9.5 Threats
  • 5.10 Value Chain Analysis
    • 5.10.1 Overview
    • 5.10.2 Research and Development
    • 5.10.3 Raw Material Procurement
    • 5.10.4 Manufacturing
    • 5.10.5 Marketing
    • 5.10.6 Distribution
    • 5.10.7 End-Use
  • 5.11 Porters Five Forces Analysis
    • 5.11.1 Overview
    • 5.11.2 Bargaining Power of Buyers
    • 5.11.3 Bargaining Power of Suppliers
    • 5.11.4 Degree of Competition
    • 5.11.5 Threat of New Entrants
    • 5.11.6 Threat of Substitutes

6 Market Breakup by Drug Class

  • 6.1 Nucleoside Reverse Transcriptase Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Multi-Class Combination Products
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Protease Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 HIV Integrase Strand Transfer Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Fusion Inhibitors and Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia Pacific
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Middle East and Africa
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Latin America
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 HIV Drugs Manufacturing Process

  • 9.1 Product Overview
  • 9.2 Raw Material Requirements
  • 9.3 Manufacturing Process
  • 9.4 Key Success and Risk Factors

10 Competitive Landscape

  • 10.1 Market Structure
  • 10.2 Market Breakup by Key Players
  • 10.3 Profiles of Key Players
    • 10.3.1 Boehringer Ingelheim International GmbH
    • 10.3.2 Merck & Co., Inc.
    • 10.3.3 ViiV Healthcare
    • 10.3.4 AbbVie
    • 10.3.5 F. Hoffmann-La Roche Ltd.
    • 10.3.6 Teva Pharmaceutical Industries Ltd.
    • 10.3.7 Bristol-Myers Squibb
    • 10.3.8 Gilead Sciences, Inc.
    • 10.3.9 Johnson & Johnson
    • 10.3.10 Cipla Limited
    • 10.3.11 Daiichi Sankyo
    • 10.3.12 Emcure
    • 10.3.13 Hetero Drugs
    • 10.3.14 Mylan

List of Figures

  • Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2022
  • Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 7: Global: HIV Drugs Industry: SWOT Analysis
  • Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
  • Figure 9: Global: HIV Drugs Industry: Porter's Five Forces Analysis
  • Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2017 & 2022
  • Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2023-2028
  • Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2017 & 2022
  • Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2023-2028
  • Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2017 & 2022
  • Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2023-2028
  • Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2017 & 2022
  • Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2023-2028
  • Figure 32: North America: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Europe: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
  • Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)

List of Tables

  • Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 5: HIV Drugs Manufacturing: Raw Material Requirements
  • Table 6: Global: HIV Drugs Market: Competitive Structure
  • Table 7: Global: HIV Drugs Market: Key Players